Healthcare / Drug Manufacturers - Specialty & GenericBSE
$650.75
+0.75 (+0.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $71.4M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.4B
P/E
47.0x
↑EV/EBITDA
22.4x
↑ROE
10.9%
↑Gross Margin
61.7%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+6.6%
FCF CAGR
—
FCF margin
6.5%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.09B · net income $177.7M · FCF $71.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.09B | $1.09B | $1.09B | $1.25B | $902.2M |
| Net Income | $177.7M | $177.7M | $231.0M | $281.1M | $170.2M |
| EBITDA | $380.5M | $380.5M | $429.4M | $448.2M | $264.2M |
| EPS | 13.84 | 13.84 | 17.98 | 22.34 | 14.01 |
| Gross Margin | 61.7% | 61.7% | 67.0% | 53.1% | 47.7% |
| Operating Margin | 22.5% | 22.5% | 27.3% | 28.6% | 22.5% |
| Net Margin | 16.3% | 16.3% | 21.3% | 22.5% | 18.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.26 | 0.30 | 0.38 |
| Current Ratio | 3.96 | 3.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $71.4M | $71.4M | $74.7M | $-6.9M | $-345.7M |
| Returns | |||||
| ROE | 10.9% | 10.9% | 15.9% | 23.0% | 19.1% |
| Valuation | |||||
| P/E | 47.02 | 47.02 | 39.48 | 30.67 | 18.70 |
| EV/EBITDA | 22.42 | 22.42 | 21.90 | 19.70 | 12.99 |
| P/B | 5.13 | 5.13 | 6.28 | 7.06 | 3.58 |
| Growth & Yield | |||||
| Revenue Growth | 0.6% | 0.6% | -13.0% | 38.3% | — |
| EPS Growth | -23.0% | -23.0% | -19.5% | 59.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
61.0%
EPS terminal req.
$57.74
Spread vs growth
-84.0%
5Y implied EPS CAGR
38.2%
EPS terminal req.
$69.87
Spread vs growth
-61.3%
10Y implied EPS CAGR
23.3%
EPS terminal req.
$112.53
Spread vs growth
-46.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.0%
Start / end P/E
33.8x → 47.0x
EPS bridge
17.98 → 13.84
Residual
-9.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.